Outcomes of Isolated LCx Occlusion
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAssiut University
About this trial
To assess procedural success and short term clinical outcomes of primary PCI to isolated LCx acute occlusion.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients presented to Assiut University heart hospital with STEMI who underwent primary PCI that revealed isolated LCx acute occlusion (single culprit artery) between January 2018 to January 2025 will be included.
Disqualifiers
None
Trial population
Baseline demographic, angiographic and clinical data, including cardiovascular risk factors, will be retrospectively collected. For follow up, we will contact every patient included in our study to ask about MACE.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
50 Participants
are grouped into 1 trial groupGroup A: Follow up after PPCI
Trial outcomes
Primary outcomes
1
Complications of PPCI to LCx occlusion
defined as angiographic success without in-hospital complications). Angiographic success (defined as in-stent residual stenosis ≤30% without serious angiographic complications (severe coronary dissection impairing flow \[type D-F\], perforation, abrupt closure or no reflow) .
Time frame
6 monthsSecondary outcomes
1
Long follow up of outcomes of PPCI of LCx outcomes
The secondary endpoint will be assessment of MACE at 6 months following the index procedure. MACE ( defined as the composite of all-cause mortality, target lesion revascularization, stent thrombosis, documented atrial fibrillation and development of heart failure).
Time frame
6 monthsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: